Multiple Applications

Cancer Detection

Revolutionizing prostate and ovarian cancer diagnostic methodologies

75% of prostate biopsies (£1,000+) are negative driven by overdiagnosis due to false positives driven by PSA testing.

Ovarian cancer has higher mortality than breast and prostate cancer due to non-specific symptoms, lack of effective screening tests, anatomical location, misdiagnosis and late onset of symptoms.

Obstetrics Insights

Automated analysis for enhanced obstetric care and outcomes

Fetal Growth Restriction (FGR) Affects ~10% of all births. 50% of those monitored do not suffer FGR and 8% of FGR cases are undiagnosed until birth. Missed FGR accounts for about 50% of all stillbirths before 34 weeks of gestation and drives higher risk for a range of major complications.

Nephrology Solutions

Improving kidney health assessments through advanced imaging techniques

Estimated Glomerular Filtration Rate (‘eGRF’) requires a blood sample and suffers from variability. More importantly it is an indirect measure that may not be accurate across ethnic groups and different body types. Cortical perfusion directly correlates to GFR.

Validated quantification of tissue perfusion for better diagnostics

We characterize tissue perfusion to give reproducible metrics that allow us to better detect and characterise disease.

Comprehensive Analysis

Ann O'Neill, Executive Director and Alicia Loehlein, Associate Director

Co-Founders, Measure the Placenta, USA

"As a patient advocacy group focused on identifying issues with the placenta during pregnancy, we are incredibly excited about the potential of Oxailis' AI-driven ultrasound technology to revolutionize pregnancy care. Identifying complications early in pregnancy would lead to improved outcomes for both mothers and babies, as well as reducing medical costs. We can only wish this was available during our pregnancies, as our babies' outcomes could have been drastically different"